...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: News !!!
5
Feb 26, 2018 07:39AM
1
Feb 26, 2018 09:05AM

Feb 26, 2018 09:30AM
5
Feb 26, 2018 09:43AM
2
Feb 26, 2018 10:17AM
2
Feb 26, 2018 10:24AM
4
Feb 26, 2018 10:32AM
3
Feb 26, 2018 11:00AM
2
Feb 26, 2018 11:12AM
3
Feb 26, 2018 12:29PM

Feb 26, 2018 02:00PM

"Am I correct that you stated previously, or maybe someone  else,that the rate of mace in this population  would be between 11 and 12 percent on standard treatment?"

You are kind of correct. In EXAMINE trial, which influenced BETonMACE design, the event rate was ~11-12% at 18 months. BETonMACE is showing 8% event rate (0.08 per patient year). In my opinion, to best compare these two figures is to express the BETonMACE figure as events per 1.5 years (18 months), which would be 0.12 or 12%.

BDAZ


Feb 26, 2018 07:39PM
2
Feb 26, 2018 08:30PM
2
Feb 27, 2018 04:31AM
3
Feb 27, 2018 06:58AM
4
Feb 27, 2018 11:59AM
4
Feb 27, 2018 05:31PM
3
Feb 27, 2018 06:53PM
4
Feb 27, 2018 08:44PM
3
Feb 27, 2018 10:48PM
Share
New Message
Please login to post a reply